ACADIA Pharmaceuticals Inc
ACADHealthcare|Biotechnology|USA
$26.22
-0.19 (-0.72%)
DCF (FCF)
$4.73
Tangible Book
$6.67
Graham Number
$18.18
Earnings Power
$5.25
Clinical Trials (54)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05357612 Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases | Neurodegenerative Diseases, Parkinson Disease | P4 | Recruiting | 75 | Open-label | Pimavanserin |
| NCT06173531 Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome | Hyperphagia in Prader-Willi Syndrome | P3 | Active | 170 | RCT, Double-blind | Carbetocin, Placebo |
| NCT06159673 ACP-204 in Adults With Alzheimer's Disease Psychosis | Alzheimer's Disease Psychosis | P2P3 | Recruiting | 1,074 | RCT, Double-blind | ACP-204, Placebo |
| NCT05999240 Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder | Autism Spectrum Disorder | P2 | Recruiting | 30 | RCT, Double-blind | Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID], Placebo |
| NCT07284667 ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant | P2 | Recruiting | 153 | RCT, Double-blind | ACP-211, Placebo |
| NCT07029581 Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis | Lewy Body Dementia Psychosis | P2 | Recruiting | 180 | RCT, Double-blind | ACP-204, Placebo |
| NCT05895513 Pimavanserin and Aggression and Social Cognition. | Intermittent Explosive Disorder | P2 | Recruiting | 35 | RCT, Double-blind | Pimavanserin 34 mg, Placebo |
| NCT06864741 Virtual Reality Rehabilitation for Stroke Patients in the Hospital and at Home. | Stroke Acute | N/A | Recruiting | 40 | RCT, Single-blind | — |
| NCT04809116 Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept | Insomnia Chronic, Posttraumatic Stress Disorder | P4 | Withdrawn | — | Open-label | Pimavanserin |
| NCT04292223 Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis | Parkinson Disease Psychosis | P4 | Completed | 29 | Open-label | Pimavanserin |
| NCT02545634 Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children | Attention Deficit Hyperactivity Disorder, Anxiety | P4 | Unknown | 100 | RCT, Double-blind | — |
| NCT07095465 Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis | Lewy Body Dementia Psychosis | P3 | By Invite | 126 | Open-label | ACP-204 |
| NCT03623321 Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease | Neuropsychiatric Symptoms Related to Neurodegenerative Disease | P3 | Completed | 595 | Open-label | Pimavanserin |
| NCT04531982 Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia | Schizophrenia | P3 | Completed | 454 | RCT, Double-blind | Pimavanserin, Placebo |
| NCT05523895 Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder | Irritability Associated With Autism Spectrum Disorder | P2P3 | Completed | 237 | RCT, Double-blind | Pimavanserin, Placebo |
| NCT03968159 Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment | Adjunctive Treatment of Major Depressive Disorder | P3 | Completed | 298 | RCT, Double-blind | Pimavanserin, Placebo |
| NCT06420297 OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome | Hyperphagia in Prader-Willi Syndrome | P3 | By Invite | 160 | Open-label | Carbetocin |
| NCT06194799 ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study | Alzheimer's Disease Psychosis | P3 | By Invite | 752 | Open-label | ACP-204 |
| NCT04181723 Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™) | Rett Syndrome | P3 | Completed | 187 | RCT, Double-blind | Trofinetide |
| NCT04000009 Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment | Adjunctive Treatment of Major Depressive Disorder | P3 | Terminated | 235 | Open-label | Pimavanserin |
| NCT04279314 Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome | Rett Syndrome | P3 | Completed | 154 | Open-label | Trofinetide |
| NCT03325556 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis | Dementia-related Psychosis | P3 | Completed | 392 | RCT, Double-blind | Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg |
| NCT01174004 A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis | Parkinson's Disease Psychosis | P3 | Completed | 199 | RCT, Double-blind | pimavanserin tartrate, placebo |
| NCT00477672 A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis | Parkinson's Disease Psychosis | P3 | Completed | 298 | RCT, Double-blind | Pimavanserin tartrate (ACP-103), Pimavanserin tartrate (ACP-103), Placebo |
| NCT04776746 Open-Label Extension Study of Trofinetide for Rett Syndrome | Rett Syndrome | P3 | Terminated | 77 | Open-label | trofinetide |
| NCT03121586 Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia | Schizophrenia | P3 | Terminated | 995 | Open-label | Pimavanserin |
| NCT03575052 A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease | Neuropsychiatric Symptoms Related to Neurodegenerative Disease | P3 | Completed | 784 | RCT, Double-blind | Pimavanserin, Placebo |
| NCT05555615 Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder | Irritability Associated With Autism Spectrum Disorder | P2P3 | Terminated | 209 | Open-label | Pimavanserin |
| NCT04988867 An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome | Rett Syndrome | P2P3 | Terminated | 15 | Open-label | Trofinetide |
| NCT00550238 A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis | Parkinson's Disease Psychosis | P3 | Completed | 459 | Open-label | Pimavanserin tartrate (ACP-103) |
| NCT00658567 A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis | Parkinson's Disease Psychosis | P3 | Completed | 123 | RCT, Double-blind | Pimavanserin tartrate (ACP-103), Pimavanserin tartrate (ACP-103), Pimavanserin tartrate (ACP-103) |
| NCT02970292 Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1) | Schizophrenia | P3 | Completed | 396 | RCT, Double-blind | Pimavanserin, Placebo |
| NCT03118947 A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease | Agitation and Aggression in Alzheimer's Disease | P2 | Completed | 79 | Open-label | Pimavanserin |
| NCT02992132 Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE) | Agitation and Aggression in Alzheimer's Disease | P2 | Terminated | 111 | RCT, Double-blind | Pimavanserin 34 mg, Pimavanserin 20 mg |
| NCT02035553 A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis | Alzheimer's Disease Psychosis | P2 | Completed | 181 | RCT, Double-blind | Pimavanserin tartrate, Placebo |
| NCT05008835 Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee | Osteoarthritis Pain | P2 | Terminated | 61 | RCT, Double-blind | ACP-044 Dose A, ACP-044 Dose B, Placebo |
| NCT04164758 Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine | Parkinson's Disease | P2 | Terminated | 11 | RCT, Double-blind | Pimavanserin, Quetiapine |
| NCT03947216 Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. | Parkinson Disease | P2 | Completed | 117 | RCT, Double-blind | Active drug: pimavanserin 17mg (2 strength tablets), Placebo: 2 tablets containing same excipients except active compound |
| NCT00087542 Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug | Hallucinations, Psychoses | P2 | Completed | 60 | RCT, Double-blind | ACP-103 |
| NCT01518309 An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients | Parkinson's Disease Psychosis | P2 | Completed | 39 | Open-label | pimavanserin tartrate (ACP-103) |
| NCT00490516 ACP-104 in Acutely Psychotic Subjects With Schizophrenia | Schizophrenia | P2 | Completed | 247 | RCT, Double-blind | ACP-104, ACP-104, Placebo |
| NCT04855240 Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy | Acute Postoperative Pain, Bunionectomy | P2 | Completed | 239 | RCT, Double-blind | ACP-044 Dose A, ACP-044 Dose B, Placebo |
| NCT03482882 Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression | Treatment of Depression in Adults With Parkinson's Disease (PD) | P2 | Completed | 47 | Open-label | Pimavanserin |
| NCT03018340 Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY) | Adjunctive Treatment of Major Depressive Disorder | P2 | Completed | 207 | RCT, Double-blind | Pimavanserin |
| NCT03994965 The Sub-Sero Study | Schizophrenia, Psychosis | P2 | Withdrawn | — | Open-label | Pimavanserin 34 milligrams (MG) [Nuplazid] |
| NCT02970305 Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE) | Schizophrenia | P2 | Completed | 403 | RCT, Double-blind | Pimavanserin, Placebo |
| NCT00361166 Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone | Schizophrenia | P2 | Completed | 400 | RCT, Double-blind | ACP-103 |
| NCT02035878 Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression | Anxiety, Depression | P2 | Unknown | 75 | RCT, Double-blind | Placebo |
| NCT00628420 Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics | Schizophrenia | P1 | Completed | 45 | RCT, Double-blind | ACP-104, ACP-104, Placebo |
| NCT05240339 Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD) | Parkinson Disease, Parkinson Disease Psychosis | Completed | 38 | — | — | |
| NCT02762591 Expanded Access of Pimavanserin for Patients With PD Psychosis | Parkinson's Disease Psychosis | APPROVED_FOR_MARKETING | — | — | Pimavanserin tartrate | |
| NCT05796167 Pimavanserin for Sleep in Parkinson Disease | Parkinson Disease | Early P1 | Withdrawn | — | Open-label | Pimavanserin |
| NCT03152292 The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study | Parkinson Disease Psychosis | Terminated | 764 | — | — | |
| NCT06575621 Knee-hip Surgery Wait-list Support Program | Knee Arthropathy, Hip Arthropathy | N/A | Not Yet Recruiting | 50 | Open-label | — |